Lirilumab/Opdivo combo shows ‘no clear evidence of benefit’

24th November 2017 Uncategorised 0

Shares in Innate Pharma plunged near 50 percent on Thursday after it said that a combination of lirilumab and Bristol-Myers Squibb’s PD-1 inhibitor Opdivo failed to provide clear evidence of benefit in patients with squamous cell carcinoma of the head and neck.

More: Lirilumab/Opdivo combo shows ‘no clear evidence of benefit’
Source: News